FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. The honorees “stand as a driving force, ensuring diverse perspectives on scientific breakthroughs and groundbreaking therapies,” according to the publication. “Their achievements serve a ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2023. “Our fourth quarter was the culmination of an exceptional year, where we delivered consistent, strong growth in both revenue and test volume,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Our perfo ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Catherine Schulte - Baird Mason Carrico - Stephens Mark Massaro - BTIG Operator Good afternoon and welcome to Castle Bioscie ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ (State or other jurisdiction of incorporation or organization) 505 S. Friendswood Drive, Suite 401, Friendswood, ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Carl Nixon - Canacord Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Mason Carrick - Stevens Catherine Schulte - Baird Mark Massaro - BTIG Operator G ...

34 Table of Contents The following table provides a disaggregation of net revenues by type (in thousands): | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------|-------|-------|-------------------------|------------------------|--------|-------|--------| | | | | Six Months Ended \n2023 | June 30, \n(unaudited) | 2022 | | Change | | (1) Dermatologic | | $ | 78,941 | $ | 56,236 | $ | 22,705 | | (2) Non-Dermatologic | | | 13,234 | | 5,454 | | 7,780 | | Total net revenues | | $ | 92,175 | ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Catherine Schulte - Baird Mark Massaro - BTIG Sung Ji Nam - Scotiabank Operator Good afternoon, and welcome to Castle Biosciences ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | 2 Financial Performance Summary Q1 2023 1See Non-GAAP reconciliations at the end of this presentation. 2Year-over-year change in cash, cash equivalents and marketable securities includes the acquisition of AltheaDx in April 2022 and payout of annual bonuses in Q1 2023, among other uses. Key Q1 2023 Accomplishments Published prospective, multicenter study, called DECIDE,1 showing DecisionDx-Melanoma test resul ...

December 31, 2022 AltheaDx, Inc. Unaudited Pro Forma Financial Information Property and equipment, net consisted of the following (in thousands): 8. Goodwill and Other Intangible Assets, Net Table of Contents CASTLE BIOSCIENCES, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued) (UNAUDITED) | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------|-------|--------------------------------|-------|-------------------------------------------------------- ...

$13.8 $22.8 $51.9 $62.6 $94.1 $137.0 2017 2018 2019 2020 2021 2022 58% 46% Near- to Mid-term Growth Mid- to Long-term Growth 11 1Due to COVID-19, cutaneous melanoma diagnoses were down 20% for 2020; 2 Cutaneous melanoma diagnoses were down 11% for 2021. Delivered strong year-over-year growth in revenue (met top end of guided range) and test report volume (total test reports delivered in 2022 were 44,419 up 58% over 2021) 1ADLT=Advanced Diagnostic Laboratory Test 5 Customer & Solution Centric Exceptional Emp ...